Cg Oncology Inc.
XNAS:CGON 4:00:00 PM EDT
| Market Cap (Intraday) | 6.20B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $68.43 |
| 50-Day MA | $61.94 |
| 200-Day MA | $43.71 |
Cg Oncology Inc. Stock, XNAS:CGON
400 Spectrum Center Drive, Suite 2040, Irvine, California 92618
United States of America
Phone: +1.949.409.3700
Number of Employees: 61
Description
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.